Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. ciênc. farm. básica apl ; 41: [11], 01/01/2020. graf, tab, ilus
Artículo en Inglés | LILACS | ID: biblio-1128579

RESUMEN

The skin is the largest and most exposed organ of the human body, therefore subject to diseases and alteration of its appearance. Among these alterations, the cutaneous hyperchromia may be cited. Currently, the market offers numerous products with depigmenting action to the treatment of such disorders. The aim of this work was to analyze depigmenting products commercialized in establishments in the city of Bento Gonçalves (RS, Brazil) and websites of cosmetic companies. It was found 45 products with depigmenting action and, from these, 59 different active agents were identified. The main active compounds found were kojic acid, arbutin, ascorbic acid, hydroquinone and glycolic acid. Another observed data was that in 78% of the studied products the active substances were being used in combination. The most used vehicles were also studied as a reference to the use of sunscreen in the treatment of cutaneous hyperchromia. The present work had identified in the market a variety of products with depigmentation action and, because of this, it aims to serve as a reference to the healthcare professionals, especially at the prescribing moment, looking for the best results, with regards to treatment efficiency and safety.(AU)


Asunto(s)
Humanos , Pigmentación de la Piel/efectos de los fármacos , Hiperpigmentación/tratamiento farmacológico , Cosméticos , Fármacos Dermatológicos/análisis , Arbutina , Ácido Ascórbico , Pironas , Brasil , Combinación de Medicamentos , Glicolatos , Hidroquinonas
2.
An. bras. dermatol ; 91(2): 187-195, Mar.-Apr. 2016. tab
Artículo en Inglés | LILACS | ID: lil-781375

RESUMEN

Abstract Thus far, several small studies and case reports on the use of topical immunomodulators in vitiligo have been published. We undertook a comprehensive literature review, searching for studies evaluating clinical response to tacrolimus topical therapy for vitiligo. A search was performed on PubMed/Medline using the term “vitiligo”, combined with “topical” and “ointment”. Our inclusion criteria were: use of tacrolimus ointment as monotherapy to treat vitiligo. We found 29 studies from 2002 to 2014. Overall, 709 patients were treated in 29 studies. Pooling the lesions, 50% repigmentation of vitiligo patches was never achieved before 2 months of treatment, with a peak after 6 months of therapy. The best results were obtained on lesions of the cephalic region, especially the face, with tacrolimus 0.1% ointment two times daily. The percentage of non-responsive patients ranged from 0% to 14%. Treatment was generally well-tolerated; only localized adverse effects were reported. Our objective was to verify the effectiveness and safety of tacrolimus ointment monotherapy. It has good efficacy and tolerability. At present, only small trials and case series are available in the literature. Further, standardized investigations on a larger number of patients are needed.


Asunto(s)
Humanos , Masculino , Femenino , Vitíligo/tratamiento farmacológico , Pigmentación de la Piel/efectos de los fármacos , Tacrolimus/uso terapéutico , Inmunosupresores/uso terapéutico , Pomadas , Administración Cutánea , Reproducibilidad de los Resultados , Resultado del Tratamiento
3.
Indian J Dermatol Venereol Leprol ; 2013 Nov-Dec; 79(6): 750-758
Artículo en Inglés | IMSEAR | ID: sea-154673

RESUMEN

Vitiligo is a common pigmentary disorder caused by the destruction of functional melanocytes. Vitamin D is an essential hormone synthesized in the skin and is responsible for skin pigmentation. Low levels of vitamin D have been observed in vitiligo patients and in patients with other autoimmune diseases. Therefore, the relationship between vitamin D and vitiligo needs to be investigated more thoroughly. We reviewed the literature to date regarding the role of vitamin D in skin pigmentation. Our review revealed that vitamin D defi ciency has been identifi ed in many conditions, including premature and dysmature birth, pigmented skin, obesity, advanced age, and malabsorption. Vitamin D increases melanogenesis and the tyrosinase content of cultured human melanocytes by its antiapoptotic effect. However, a few growth-inhibitory effects on melanocytes were also reported. Vitamin D regulates calcium and bone metabolism, controls cell proliferation and differentiation, and exerts immunoregulatory activities. Vitamin D exerts its effect via a nuclear hormone receptor for vitamin D. The topical application of vitamin D increased the number of L-3,4-dihydroxyphenylalanine-positive melanocytes. The topical application of vitamin D yields signifi cant results when used in combination with phototherapy and ultraviolet exposure to treat vitiligo in humans. Vitamin D decreases the expression of various cytokines that cause vitiligo. In conclusion, application of vitamin D might help in preventing destruction of melanocytes thus causing vitiligo and other autoimmune disorders. The association between low vitamin D levels and the occurrence of vitiligo and other forms of autoimmunity is to be further evaluated.


Asunto(s)
Animales , Humanos , Melanocitos/metabolismo , Pigmentación de la Piel/efectos de los fármacos , Pigmentación de la Piel/fisiología , Vitamina D/administración & dosificación , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/diagnóstico , Deficiencia de Vitamina D/tratamiento farmacológico , Vitíligo/sangre , Vitíligo/diagnóstico
4.
An. bras. dermatol ; 87(5): 685-690, Sept-Oct. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-651558

RESUMEN

BACKGROUND: Vitiligo is a prevalent skin pigmentation disorder worldwide. The treatments available still offer limited results to some patients. For patients with clinically stable vitiligo, melanocyte transplantation is an appropriate treatment option, and the technique of autologous punch grafting shows good repigmentation. OBJECTIVE: To evaluate the effect of topical mometasone on the halos of repigmentation after autologous punch grafting in patients with clinically stable vitiligo. METHODS: Between 2009 and 2010, 11 patients with clinically stable vitiligo (7 generalized, 2 focal and 2 segmental) underwent autologous punch grafting in the achromic patches. According to the clinical type of vitiligo, patients were instructed to use the corticosteroid ointment during 6 months, only on a few grafted lesions. In the first month, the mometasone ointment was used twice a day and after that just once. They were reassessed 1, 3 and 6 months after the procedure. Grafted halos were photographed and recorded using the software fotofinder. After 6 months, all the treated and untreated areas of the repigmentation halos were measured and analyzed comparatively. RESULTS: The median area of the repigmentation halos after 6 months of treatment with mometasone was larger (25,96 mm² ) than the one of the untreated halos (13,86 mm² ), showing a statistically significant difference (p = 0,026). CONCLUSION: In this study, the use of mometasone ointment increased the area of the repigmentation halos after punch grafting. However, this should be further investigated in larger samples in order to validate this positive action in the treatment of stable vitiligo.


FUNDAMENTOS: Vitiligo é um transtorno de pigmentação freqüente na população mundial. Seu tratamento ainda oferece resultados limitados em alguns pacientes. Nos casos de vitiligo estável clinicamente, o transplante de melanócitos tornase uma opção terapêutica, sendo a técnica de enxertos autólogos por punch empregada com boa resposta na repigmentação. OBJETIVOS: Estudar a ação do corticoesteróide tópico mometasona sobre halos de repigmentação após enxertos autólogos por punch em pacientes com vitiligo estável clinicamente. MÉTODOS: Entre 2009 e 2010, 11 pacientes com vitiligo estável (7 do tipo generalizado, 2 focal e 2 segmentar) foram submetidos a enxertos autólogos por punch nas máculas acrômicas. Conforme o tipo clínico do vitiligo, os pacientes eram orientados a aplicar pomada de mometasona por 6 meses em lesões enxertadas selecionadas individualmente. No primeiro mês, a aplicação era 2 vezes ao dia e nos demais, apenas uma vez ao dia. Eram reavaliados nos meses 1, 3 e 6 após enxertos cujos halos eram fotografados e registrados pelo software fotofinder. No fim do 6̊mês, todas as áreas dos halos de repigmentação com e sem mometasona foram mensuradas e analisadas comparativamente. RESULTADOS: A mediana da área dos halos de repigmentação após os 6 meses com mometasona foi superior (25,96 mm² ) comparada àquela sem mometasona (13,86 mm² ), com diferença estatisticamente significante (p=0,026). CONCLUSÃO: Em nossa casuística, o uso da mometasona tópica determinou incremento dos halos de repigmentação após enxertia. A amplificação da amostra se faz necessária em estudos posteriores a fim de ratificar esta ação positiva da mometasona no tratamento do vitiligo estável.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Adulto Joven , Antiinflamatorios/uso terapéutico , Epidermis/trasplante , Pregnadienodioles/uso terapéutico , Trasplante de Piel , Pigmentación de la Piel/efectos de los fármacos , Vitíligo/terapia , Terapia Combinada/métodos , Trasplante Autólogo , Resultado del Tratamiento
5.
J Postgrad Med ; 2008 Oct-Dec; 54(4): 332-4
Artículo en Inglés | IMSEAR | ID: sea-116231

RESUMEN

Nicolau syndrome (NS) is a rare complication of an intramuscular injection characterized by severe pain, skin discoloration, and varying levels of tissue necrosis. The case outcomes vary from atrophic ulcers and severe pain to sepsis and limb amputation. We describe a case of a seven-year-old boy with diagnosis of NS after intramuscular benzathine penicillin injection to the ventrolateral aspect of the left thigh. Characteristic violaceous discoloration of skin and immediate injection site pain identified it as a case of NS. The case was complicated by rapid progression of compartment syndrome of the lower limb, proceeding to acute renal failure and death. Associated compartment syndrome can be postulated as a poor prognostic factor for NS.


Asunto(s)
Niño , Síndromes Compartimentales/etiología , Erupciones por Medicamentos/complicaciones , Resultado Fatal , Humanos , Inyecciones Intramusculares/efectos adversos , Lesión Renal Aguda/etiología , Masculino , Dolor/inducido químicamente , Penicilina G Benzatina/administración & dosificación , Enfermedades Cutáneas Vasculares/inducido químicamente , Pigmentación de la Piel/efectos de los fármacos , Síndrome , Muslo
8.
Journal of Korean Medical Science ; : 58-64, 2002.
Artículo en Inglés | WPRIM | ID: wpr-82624

RESUMEN

The mechanisms of estrogen and progesterone in human cutaneous pigmentation are largely unknown. The molecular identification of estrogen receptor (ER) and progesterone receptor (PR) in the human melanocytes is of great importance to understand the mechanisms. We performed immunocytochemistry analysis and demonstrated that ER and PR were expressed in the cytoplasms and nuclei of human melanocytes. Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequence analysis confirmed the expression of ER and PR at the transcriptional level. Despite of the presence of ER and PR, the physiological and pregnant levels of estrogen and progesterone showed inconsistent effects on the proliferation and tyrosinase activity of cultured human melanocytes. These results suggest that human melanocytes express ER and PR, which have a donor-specific action in human pigmentation. Further studies are needed to elucidate the induction mechanism and functions of these receptors, and the role of estrogen and progesterone in melanocytes.


Asunto(s)
Adulto , Humanos , Células Cultivadas , Estrógenos/farmacología , Expresión Génica , Melanocitos/citología , Mitógenos/farmacología , Técnicas de Cultivo de Órganos , Progesterona/farmacología , Receptores de Estrógenos/genética , Receptores de Progesterona/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Piel/efectos de los fármacos , Pigmentación de la Piel/efectos de los fármacos , Donantes de Tejidos
10.
Indian J Physiol Pharmacol ; 1989 Apr-Jun; 33(2): 101-6
Artículo en Inglés | IMSEAR | ID: sea-106671

RESUMEN

Adrenaline was effective in aggregating the melanosomes both in innervated as well as denervated melanophores. Isotonic KCl could induce pigment aggregation only in innervated melanophores. Adrenaline- and K+-induced pigment aggregation response in these melanophores was blocked by phentolamine: propranolol failed to do so. It is suggested that the chromatic nerves in the fish, Labeo rohita are adrenergic and via post-synaptic alpha-adrenoceptors, control the melanosome aggregation.


Asunto(s)
Animales , Carpas/fisiología , Cyprinidae/fisiología , Epinefrina/farmacología , Femenino , India , Masculino , Melanóforos/efectos de los fármacos , Neuronas/efectos de los fármacos , Fentolamina/farmacología , Potasio/farmacología , Propranolol/farmacología , Pigmentación de la Piel/efectos de los fármacos , Sistema Nervioso Simpático/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos
11.
An. bras. dermatol ; 62(2): 97-100, mar.-abr. 1987. ilus
Artículo en Portugués | LILACS | ID: lil-40956

RESUMEN

Apresenta-se um caso de pigmentaçäo azul acinzentada na face de um paciente fazendo uso de amiodarona. Tecem-se consideraçöes sobre esta entidade e comenta-se bibliografia recente sobre o assunto, ressaltando ser este o primeiro caso registrado no Rio de Janeiro


Asunto(s)
Anciano , Humanos , Masculino , Amiodarona/efectos adversos , Trastornos por Fotosensibilidad/inducido químicamente , Pigmentación de la Piel/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA